Beam Therapeutics Inc. announced that Eli Lilly and Company (Lilly) has agreed to acquire certain rights under Beam's amended collaboration and license agreement with Verve Therapeutics Inc. (Verve), including Beam's opt-in rights to co-develop and co-commercialize Verve's base editing programs for cardiovascular disease, which includes programs targeting PCSK9, ANGPTL3 and an undisclosed liver-mediated, cardiovascular target. Under the terms of the agreement, Beam will receive a $200 million upfront payment and $50 million equity investment. Beam is also eligible to receive up to $350 million in potential future development-stage payments upon the completion of certain clinical, regulatory and alliance events for a total of up to $600 million in potential total deal consideration.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.01 USD | -3.50% | +0.92% | -11.79% |
07/05 | Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates | MT |
07/05 | Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.79% | 1.89B | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+45.26% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- BEAM Stock
- News Beam Therapeutics Inc.
- Eli Lilly and Company Agree to Acquire Beam's Opt-In Rights to Verve Therapeutics' Base Editing Programs for Cardiovascular Disease